We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Nektar Hit With Derivative Suit Over Drug Trial Results

Law360 (February 14, 2019, 7:49 PM EST) -- Nektar Therapeutics was hit Wednesday with a stockholder derivative suit in Delaware federal court alleging the pharmaceutical company's executives misled shareholders about the experimental results of its leading cancer drug and...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Delaware

Nature of Suit

Securities/Commodities

Judge

Subscribers Only

Date Filed

February 13, 2019

Law Firms

Companies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.